Le Lézard
Classified in: Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

National Research Corporation to Broadcast Its First Quarter 2024 Conference Call Live on the Internet


National Research Corporation (NASDAQ:NRC) today announced that it will provide an online web simulcast of its 2024 first quarter earnings conference call on Wednesday, May 8, 2024. The Company's results for the 2024 first quarter will be released after the close of the market on Tuesday, May 7, 2024.

The live broadcast of National Research Corporation's conference call will begin at 11:00 a.m. Eastern Time on May 8, 2024. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.

A live audio webcast can be accessed at https://events.q4inc.com/attendee/554254445. The webcast will also be available for replay.

For more than 40 years, NRC Health has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focused approach, unmatched market research, and emphasis on consumer preferences are transforming the healthcare experience, creating strong outcomes for patients and entire healthcare systems. For more information, email [email protected], or visit www.nrchealth.com.


These press releases may also interest you

at 21:41
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or "the Company") and certain of its officers....

at 21:30
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc.  today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a...

at 21:22
Fred Ghodoosi Joins L&F Brown as Senior Litigation Counsel
L&F Brown, P.C., a law firm serving the needs of Fintech, Legaltech and other innovative companies, has announced the addition of?Fred Ghodoosi?as Senior Litigation Counsel. Throughout his career, Ghodoosi has been counsel for Fortune 100 companies,...

at 21:02
THE HEMPSHIRE GROUP, INC. ANNOUNCES A DELAY IN FILING 2023 ANNUAL FINANCIAL STATEMENTS AND RELATED MANAGEMENT'S DISCUSSION AND ANALYSIS
The Hempshire Group, Inc. ("Hempshire" or the "Company"), a California-based non-tobacco and non-nicotine smokables alternatives company that formulates and sells its own proprietary brand of cannabidiol hemp smokes ("CBD Hemp Smokes") under the...

at 21:00
Landlord Studio Launches Free Listing Syndication Ahead of Peak Moving Season
Landlord Studio, the leading property management accounting software for self-managing landlords announced its new free listing syndication feature in partnership with Zillow and Zumper. Charles Chan, CEO of Landlord Studio said, "We're delighted to...

at 20:12
FLJ GROUP LIMITED RECEIVES NASDAQ DETERMINATION LETTER ON COMPLIANCE PLAN
FLJ Group Limited (the "Company"), today announced that it has received a letter dated April 25, 2024 (the "Determination Letter") from the listing qualifications department staff (the "Staff") of The Nasdaq Stock Market ("Nasdaq"), notifying that...

More news about Business...


News published on and distributed by: